Immune mechanisms that control diseases include mainly the induction of neutralizing antibodies (humoral immunity) and generation of T cells (cell-mediated immunity), including CD4 ϩ helper (Th) and CD8 ϩ cytotoxic (cytotoxic T-lymphocyte) responses. T helper cells often segregate into dichotomous cytokine-secreting phenotypes: Th1 cells secreting gamma interferon (IFN-␥), interleukin-2 (IL-2), and lymphotoxin aid cell-mediated immunity, whereas Th2 cells producing IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 facilitate B-cell antibody production (22, 30) . CD8 ϩ T cells are principally involved in killing infected targets and tumors (18) .
The success of vaccines depends on two key aspects: identification of specific antigenic targets and the ability to evoke a strong and appropriate immune response. Over the past decade, considerable progress has been made toward identification, purification, and/or synthesis of key antigenic determinants of pathogens and tumors (7, 24) . However, relatively poor immunogenicity may be expected from such highly purified proteins and/or peptides, limiting their ability to induce a strong protective immune response. While coadministering antigens (Ags) with immunostimulating adjuvants often facilitates a strong immune response, many adjuvants have undesirable side effects such as severe inflammatory responses that preclude their use in humans. Indeed, the only adjuvant currently approved universally for use in humans is alum (aluminum hydroxide), which is a relatively weak potentiator of cellmediated immune responses (16) .
Liposomes composed of synthetic esters have been explored as possible Ag carrier vehicles, and a liposome-based vaccine against hepatitis A has been licensed for humans (2) . However, while liposomes provide an antigenic depot, often codelivery of additional adjuvants such as lipid A or cholera toxin (CT) is required for effective immunity (17, 34) .
The domain Archaea (archaeobacteria) consists of organisms distinct from eubacterial and eukaryotic cells in part characterized by their unique, polar lipid structures. Archaeal lipids are composed of branched phytanyl chains, which are fully saturated in many species and are attached via ether bonds to the glycerol backbone carbons at the sn-2,3 positions (19, 38) . In contrast, conventional phospholipids found in other bacteria and eukarya have fatty acyl chains, which may be unsaturated and attached via ester bonds to the sn-1,2 carbons of the glycerol. The unique structures of archaeal lipids confer considerable stability on liposomal vesicles (archaeosomes) formulated from the total polar lipids (TPL) of the different archaea (40) or from purified lipid subfractions (35) . This led us to explore the adjuvant activity of archaeosomes. In earlier studies, we reported that archaeosomes facilitated a strong antibody response to entrapped protein Ags, namely, bovine serum albumin (BSA) and CT B subunit (42) .
Adjuvants suited for vaccine formulations should display universal properties of facilitating strong and sustained immune responses against varied immunogens as well as driving the response in appropriate directions to provide protective immunity. With this aspect in mind, the current study was aimed at evaluating the ability of archaeosomes to facilitate the different facets of immune responses against entrapped protein Ags and characterizing the mechanism(s) of adjuvant action. Besides expanding our earlier studies and assessing the ability of various archaeosome types to evoke responses to several protein Ags in mice of varying genetic backgrounds, we provide here evidence for induction of strong Ag-specific Th2 and Th1 (cell-mediated) immunity, memory response, and Ag-dependent cycling of memory T cells.
MATERIALS AND METHODS
Growth of archaea and extraction of lipids. Halobacterium salinarum ("Halobacterium cutirubrum") (ATCC 33170), Methanobacterium espanolae GP9 (DSM 5982), Methanobrevibacter smithii ALI (DSM 2375), Methanosphaera stadtmanae MCB-3 (DSM 3091), Thermoplasma acidophilum 122-1B3 (ATCC 27658), Methanosarcina mazei S-6 (DSM 2053), and Natronobacterium magadii MS3 (ATCC 43099) were cultivated in 75-to 250-liter fermentors as described earlier (10) . Total lipids were extracted from frozen cell pastes, and the TPL were collected as the acetone-insoluble fraction (10) .
Preparation and characterization of archaeosomes and conventional liposomes. Archaeosomes were composed of the TPL from the different archaea mentioned above except for PGP-0-CH 3 archaeosomes. These were prepared from PGP-0-CH 3 (phosphatidylglyceromethylphosphate diether analog [20] ) isolated from H. salinarum with a purity of at least 79%, determined by negative-ion fast atom bombardment-mass spectrometry. L-␣-Dimyristoylphosphatidylcholine (DMPC), L-␣-dimyristoylphosphatidylglycerol (DMPG), and cholesterol (CHOL) were purchased from Sigma Chemical Co., St. Louis, Mo., for the preparation of conventional liposomes, defined herein as DMPC-DMPG-CHOL (1.8:0.2:1.5 molar ratio) unless otherwise stated. Vesicles were prepared by pressure extrusion at 23°C with 400-nm-pore-size filters (9) . Briefly, 20 mg of dried lipid was hydrated in 1 ml of phosphate-buffered saline (PBS) containing the protein Ag (10 mg/ml). Ag that was not associated with the vesicles was removed by ultracentrifugation (200,000 ϫ g max for 30 min) three times from 7-ml volumes of PBS. Mean vesicle diameters were determined by numberweighted Gaussian size distributions with a Nicomp Particle sizer (model 370; Nicomp, Santa Barbara, Calif.). The amount of protein incorporated into the vesicles was estimated, after lipid removal (45) , by the sodium dodecyl sulfate (SDS)-Lowry method and comparison with standard curves constructed for the relevant protein. The ratio of protein to lipid (micrograms per milligram) is based on the salt-free dry weights of the vesicles.
Encapsulation versus surface localization of Ag in lipid vesicles. Archaeosomes and conventional liposomes containing BSA were incubated with protease type IV from Streptomyces griseus (Sigma Chemical Co.). The assay consisted of incubating 50 l of BSA-vesicles with, or without, 0.028 U of protease for 2 h at 35°C. Protease inhibitors, phenylmethylsulfonyl fluoride and leupeptin (Sigma), were then added from ethanolic solutions to achieve 50 M each. After 0.5 h at ambient temperature, 5 g of hen egg lysozyme (HEL) (Sigma) was added just prior to vesicle lysis with SDS sample buffer, and samples of 50 l were placed immediately in a boiling water bath for 3 min. SDS-polyacrylamide gel electrophoresis and quantitative densitometry on bands stained with Coomassie brilliant blue R-250 (Bio-Rad, Richmond, Calif.) were done as described elsewhere (42) . Controls were included within each experiment to verify that the protease inhibitors were effective and to confirm digestion of surface-bound Ag. For the latter, BSA was surface bound by incubating empty H. salinarum archaeosomes overnight at 4°C with 10 mg of BSA/ml of PBS, followed by one wash. Interfering bands were absent from all vesicle types lacking Ag.
Mice, immunization, and Ags. Inbred, 6-to 8-week-old female BALB/c and C57BL/6 mice were purchased from Charles River Laboratories (St. Constant, Canada), and C3H/HeJ mice were from The Jackson Laboratory (Bar Harbor, Maine). Mice were maintained in the animal facility of the Institute for Biological Sciences, National Research Council, in accordance with guidelines of the Canadian Council on Animal Care.
Groups of four to six mice received two immunizations of the Ag in PBS (no adjuvant), in alum or Freund's adjuvant (FA), or entrapped in archaeosomes or conventional liposomes, as specified in the figure legends. Immunization volume was 100 to 200 l, Ag dose was 8 to 15 g/injection, and lipid concentration was 0.2 to 1.7 mg/injection. For alum immunizations, the Ag was adsorbed onto Imject alum (Pierce, Rockford, Ill.) according to the manufacturer's protocol. When FA (Sigma Chemical Co.) was used, Ag in PBS was emulsified with 62.5% complete FA in the first injection and incomplete FA for the second. Immunization routes used included intraperitoneal (i.p.), intramuscular (i.m.), and subcutaneous (s.c.) injection at the base of the tail. Ags tested included fatty-acid-free BSA, HEL, and ovalbumin (OVA), all purchased from Sigma Chemical Co.
Evaluation of antibody titers. Mice were bled either from the tail veins or by cardiac puncture, and blood was collected in Microtainer serum separator tubes (Becton Dickinson, Franklin Lakes, N.J.). After the blood was allowed to clot (1 h at 4°C), the serum was separated by centrifugation and frozen at Ϫ20°C until assayed. The antibody levels were determined by indirect Ag-specific enzymelinked immunosorbent assay (ELISA) (42) . Briefly, ELISA plates (enzyme immunoassay microtitration plates, 96 wells and flat bottom; ICN Biomedicals, Inc., Aurora, Ohio) were coated with Ag in PBS (10 g/ml), and serial twofold dilutions of serum (from individual mice) were assayed in duplicate. Horseradish peroxidase-conjugated goat anti-mouse immunoglobulin (Ig; IgG plus IgM) revealing antibody (Caltag, San Francisco, Calif.) was used to determine total antibody titers of sera. For isotyping of the sera, horseradish peroxidase-conjugated sheep anti-mouse isotype-specific (IgM-, IgG1-, IgG2a-, IgG2b-, or IgG3-specific) revealing antibodies (Serotech Inc.; distributed by Cedarlane Laboratories, Hornby, Canada) were used. The reactions were developed with the ABTS Microwell peroxidase system (Kirkegaard and Perry Laboratories, Gaithersburg, Md.), and absorbance was determined at 415 nm after 15 min. Antibody titers are represented as endpoint dilutions exhibiting an optical density of 0.3 U above background. Samples pertaining to each experiment were evaluated in the same assay.
Ag-specific proliferation of splenocytes. Cytokine assays. Cytokines produced in supernatants of Ag-stimulated cultures were measured by a sandwich ELISA (29) . Antibody pairs used included RA-6A2 (ATCC HB170) and XMG1.2-biotin (8) for IFN-␥, and 11B11 (31) and BVD6-24G2-biotin (Pharmingen Canada Inc., Mississauga, Canada) for IL-4. IFN-␥ and IL-4 standards were purchased from ID Labs, London, Canada. Duplicate standard curves were included on each plate. The sensitivities of the ELISAs were as follows: IFN-␥, Ͼ100 pg/ml, and IL-4, Ͼ15 pg/ml. Regardless of thresholds, samples from each experiment were tested in the same assay.
Cell cycle analysis. Cell cycle analysis was performed by quantitating the incorporation of DNA-binding dye (propidium iodide) by flow cytometry. Briefly, splenocytes (10 6 ) were stained with fluorescein isothiocyanate-conjugated anti-CD4 antibodies (Pharmingen Canada Inc.) for 30 min on ice in 50 l of RPMI medium containing 8% FBS. Cells were then washed and fixed overnight at 4°C in 1 ml of 70% ice-cold ethanol. Statistical analyses. Student's t test was done to determine statistical significance between different immunization groups for the various experiments, whereas analysis of variance (ANOVA) was used for long-term memory data to determine differences within groups (over time). P Ͻ 0.05 was considered statistically significant.
RESULTS
Choice of archaeosome types. The archaeosome types tested were chosen to represent divergent sources of TPL, based on their lipid structures. TPL with high caldarchaeol (tetraether lipids) content (T. acidophilum, Ͼ90%; M. espanolae, 65%) are known to form the most stable archaeosomes (40) . M. smithii was chosen because it represents the major archaeon resident in the human gut (28) and has a caldarchaeol content of 40 mol%. On the other hand, M. stadtmanae was included occasionally as an example of a human isolate with relatively low humoral, adjuvant properties. The phospholipids and glycolipids of H. salinarum and their sulfated forms are unique and have been characterized extensively (20) . M. mazei was of interest as a representative TPL composed almost exclusively of phosphoarchaeols with simple phospho-head groups of inositol, glycerol, serine, and ethanolamine (41) . Overall, we attempted to include at least one of the three most promising candidate archaeosomes (M. smithii, T. acidophilum, or H. salinarum) in each experiment.
BSA-archaeosomes induce strong humoral responses in mice of varying genetic backgrounds. In earlier studies, we have demonstrated the ability of several archaeosome types to induce a strong antibody response to the entrapped protein Ag (42) . The three most potent archaeosome adjuvants were tested in the current study for their ability to induce antibody responses in mice of different genetic backgrounds. Inbred mouse strains BALB/c, C57BL/6, and C3H/HeJ were immunized (i.p.) with BSA entrapped in archaeosomes comprised of TPL of different archaea or conventional liposomes or in conjunction with traditional adjuvants such as alum and FA, and anti-BSA antibodies were evaluated in the sera. Entrapment of BSA in archaeosomes resulted in elevated anti-BSA antibody titers (total IgG plus IgM) in all three mouse strains (Fig. 1) . The antibody titers achieved by entrapping BSA in archaeosomes were often comparable to that found with the potent FA and superior to those with alum and conventional liposomes. A low Ag dose (10 g/injection) was used for these experiments, demonstrating the potency of archaeosomes in facilitating a strong humoral response. Immunization with bare Ag (BSA in PBS) failed to evoke an anti-BSA antibody response, reiterating the poor immunogenicity of BSA. Thus, adjuvant activity of archaeosomes is not restricted by major histocompatibility complex haplotype of the mouse strains.
Isotype distribution. Sera collected from immunized BALB/c mice were analyzed for isotype distribution. Figure 2 indicates the serum distribution of Ag-specific IgG1, IgG2a, and IgG2b antibodies. The overall magnitude of anti-BSA-specific IgG1 antibody titers was higher than that of IgG2a and IgG2b. Nevertheless, titers of all three antibodies were significantly enhanced by BSA-archaeosomes in comparison to those induced after BSA-alum immunization (P Ͻ 0.05). The induction of both IgG1 and IgG2a antibodies by archaeosomes suggests efficient major histocompatibility complex class II presentation of the Ag leading to both a humoral (IgG1) and a cell-mediated (IgG2a; complement-fixing antibodies) response. In all cases, very little anti-BSA IgM antibodies were detected, indicating strong class switching, whereas IgG3 antibodies were undetectable (data not shown).
Internalization of BSA within archaeosomes. Because of the lack of information on the stability-degradability of archaeosomes in vivo, it was especially relevant to determine whether the protein Ag had first to be released from the internal space of the archaeosome or whether only surface-bound Ag could be presented from these relatively stable vesicles. Data showed that any BSA which was surface bound was susceptible to protease IV treatment and that surface localization versus internalization of the protein varied with the composition of the vesicle (Table 1) . However, the equivalent ability to evoke an antibody response by archaeosome types with Ͼ80% internalized Ag (M. smithii and T. acidophilum), compared to those where substantial amounts of the antigen were surface located (H. salinarum), suggested that efficient vesicle degradation had occurred in vivo.
BSA must be archaeosome associated to induce strong anti-BSA antibody titers. To test the effect of Ag encapsulation on the adjuvant action of archaeosomes, mice were immunized with BSA entrapped in archaeosomes or given separate injections of the respective weights-concentrations of empty archaeosomes and BSA. Archaeosome types were chosen to represent a high caldarchaeol (M. espanolae and T. acidophilum), a moderate caldarchaeol (M. smithii), or a simple phosphoarchaeol (M. mazei) composition. Data in Table 2 indicate that association of archaeosomes and Ag, either internalized or surface bound, is required to achieve high antibody titers, by both i.p. and i.m. routes. A significant drop in the titers was observed (for all archaeosome types irrespective of lipid composition) when empty archaeosomes and BSA were administered separately. The TPL of M. espanolae are largely uncharacterized structurally and were excluded from further studies. Similarly, M. mazei archaeosomes were excluded upon discovering that the permeability of these vesicles is dependent upon the salt form of the TPL used in their construction (32) .
Archaeosomal lipids induce superior humoral responses compared to conventional liposomal lipids. Liposomes composed of synthetic ester-lipids (conventional liposomes) have been used in the past to facilitate humoral responses to entrapped Ags (1, 14) . In earlier studies (26, 42) , as well as the current one (Fig. 1) , we have observed that archaeosomefacilitated humoral responses are significantly superior to that of conventional liposomes. The adjuvant action of conventional liposomes was directly compared to that of archaeosomes by immunizing mice with BSA entrapped in M. smithii archaeosomes, conventional DMPC-DMPG liposomes, or vesicles composed of mixtures of archaeal and ester lipid types (Table 3) . A potent anti-BSA antibody response was observed when Ag was delivered in vesicles made with 100% M. smithii TPL. This response dropped significantly (P Ͻ 0.05) with increasing proportions of DMPC-DMPG in the vesicle composition, although entrapment of Ag in 100% DMPC-DMPG vesicles yielded a moderately higher antibody titer than did bare antigen. Day 35 titers were evaluated after three (injections on days 0, 14, and 31) instead of the usual two immunizations. Even under these conditions, antibody titers induced by conventional liposomes failed to equal that of archaeosomes.
Ag/lipid ratio influences the magnitude of humoral response. One factor that may influence the adjuvant action of archaeosomes is the ratio of Ag to TPL. To specifically address this issue, mice were immunized with archaeosomes containing varying Ag loading to achieve a constant entrapped-Ag dose of 8 g/injection within a range of 0.15 to 3.1 mg (dry weight) of BSA-archaeosomes. Data in Fig. 3 demonstrate the dose-dependent effect of H. salinarum lipids on the antibody titers to the entrapped Ag. Interestingly, both very low and high doses of lipids resulted in lowering of the antibody titer, whereas intermediate doses (0.4 to 0.7 mg of lipid/injection) yielded Archaeosomes facilitate humoral responses to other entrapped protein Ags. In the studies described above, BSA was used as the model Ag for entrapment in archaeosomes and assessment of humoral responses. Potential vaccine adjuvants must possess the capacity to facilitate immune responses to a wide array of proteins irrespective of antigenic properties. Therefore, the immune response to other Ags entrapped within archaeosomes was studied. Figure 4 illustrates the antibody response in mice, obtained after immunization with two other model Ags (HEL and OVA) entrapped within M. smithii and M. stadtmanae archaeosomes. As with BSA, M. smithii archaeosomes induced markedly enhanced antibody responses in comparison to bare Ag (no adjuvant) and conventional liposomes. Interestingly, s.c. immunizations with M. smithii archaeosome-Ag resulted in very strong titers, with a dramatic enhancement (ϳ2 log) over that of alum (Fig. 4b) . Antibody titers induced by M. stadtmanae were relatively lower than that of M. smithii, as has been observed by us in other studies as well (39) .
Induction of cell-mediated immunity: archaeosomes facilitate Ag-specific proliferation of spleen cells. The induction of a cell-mediated response against Ags is often critical for sustained and effective immunity, particularly against intracellular pathogens. One of the first indicators of an effective cell-mediated immune response is the ability of lymphocyte populations of immunized mice to respond to Ag in vitro. Spleen cells from immunized mice were cultured in vitro with varying doses of Ag, and at 72 h the proliferative response was assessed by [ 3 H]thymidine incorporation. Figures 5a and b indicate the BSA-specific proliferation of spleen cells after i.p. immunization. Immunization with BSA precluded the use of FBS-supplemented medium for in vitro Ag stimulation. Therefore, the overall low levels of proliferation noted may be attributed to the inability of horse serum supplement to support strong growth. Interestingly, even under such suboptimal stimulation conditions, a dose-dependent proliferation to BSA was seen with spleen cells of mice immunized with BSA entrapped in archaeosomes. Furthermore, the proliferative response of spleen cells following archaeosome immunization was seen in both BALB/c and C3H/HeJ (lipopolysaccharide [LPS]-hyporesponsive) mice. On the other hand, conventional liposomes as well as alum failed to induce BSA-specific proliferation. Ag-specific proliferation was more pronounced with other Ags (HEL and OVA). Both HEL-archaeosomes and OVAarchaeosomes induced strong Ag-specific proliferation, as did alum (Fig. 5c and d) . Immunization by the s.c. route also resulted in similar responses. However, even with robust Ag stimulation, conventional liposomes failed to equal M. smithii archaeosomes in their ability to induce proliferation. nization failed to evoke IFN-␥ production by alum. Also, conventional liposomes induced neither IL-4 nor IFN-␥.
T. acidophilum archaeosomes induce a long-term memory response. The success of vaccines often depends on the induction of a strong persistent memory response. It was reasoned that archaeosomes, because of their stability properties (40) , may sustain Ag in vivo for longer periods than other adjuvant formulations, aiding memory responses.
Mice were immunized on days 0 and 14 with BSA-archaeosomes or other adjuvant-BSA preparations. The antibody titers were monitored in groups of mice at regular intervals, and memory responses were assessed after boosting with bare Ag in the absence of adjuvant (Fig. 7) . Figure 7a indicates that T. acidophilum archaeosomes induced a moderately enhanced primary antibody response that was sustained for nearly 200 days (P Ͻ 0.02 by ANOVA, for all time points compared to no-adjuvant immunization). Following an Ag-alone boost on day 210, a remarkable memory antibody response was seen (ϳ2-log enhancement, P ϭ 0.0004) that was sustained to at least 300 days. On the other hand, alum, despite inducing an enhanced primary response (days 35 and 70, P Ͻ 0.01 compared to no-adjuvant immunization), showed a subsequent drop in antibody titers and failed to evoke significant memory response (following Ag boost). BSA-archaeosomes prepared from the TPL of M. stadtmanae (1.1 mg/injection) resulted in low initial titers of antibody and little indication of a memory response (data not shown).
In contrast to the T. acidophilum BSA-archaeosome response noted above, BSA-archaeosomes composed of the TPL of M. mazei (0.53 mg/injection), N. magadii (0.34 mg/injection) (data not shown), or H. salinarum (Fig. 7b) failed to evoke a strong memory response despite a substantially enhanced primary response. Vesicles composed of purified PGP-0-CH 3 (the major lipid in H. salinarum TPL) showed a near-identical response to TPL of H. salinarum. FA was similar to H. salinarum vesicles by inducing a strong and sustained primary response but failing to evoke an enhanced memory response.
Induction of T-cell memory by T. acidophilum archaeosomes: increased cell cycling of CD4 ؉ cells. As antibody response to protein Ags is often T cell dependent, we tested if the strong memory antibody response induced by T. acidophilum archaeosomes was accompanied by stimulation of T helper (CD4 ϩ ) subsets. Thus, the groups of mice used for experimentation in Fig. 7a were challenged again with Ag (25 g of BSA in PBS, without adjuvant) on day 334. Seven days later, the propensity of cell cycling (based on propidium iodide staining) by splenic CD4 ϩ T cells was analyzed. The frequency of CD4 ϩ staining of spleen cell populations obtained from control (noadjuvant) or alum-or T. acidophilum archaeosome-immunized mice is shown in Fig. 8a . The total CD4 ϩ cell number was increased from 29% in the controls to 37% in the archaeosome-immunized group. Analysis of cell cycling profiles of the CD4 ϩ cells revealed that antigenic challenge of T. acidophilum archaeosome-immunized mice resulted in a dramatic increase in the numbers of cells in the S (synthetic) and G 2 /M (mitotic) phase and a concomitant decrease of cells in the G 1 (resting) phase (Fig. 8b) . In contrast, alum immunization evoked no change in the percentages of cells in the various phases compared to the no-adjuvant control. Thus, archaeosomes induced the development and persistence of memory CD4 ϩ T cells against the entrapped protein Ag.
DISCUSSION
Of the various archaeosome types tested, those composed of the TPL of T. acidophilum, H. salinarum, and M. smithii possessed the strongest adjuvant properties, often equalling that of FA and generally surpassing that of alum. The potency of archaeosomes was evident even with low Ag doses of 8 to 15 g associated with Ͻ1 mg of lipid per injection. We have related the structural properties of the TPL from the two human archaea M. smithii and M. stadtmanae to their contrasting adjuvant properties (39) and found that, although the lipids present in each TPL were remarkably similar, quantitatively there were large differences. Both archaetidyl inositol and ␤-Glcp-(1,6)-␤-Glcp-(1,1)-archaeol were associated with low adjuvant activity, whereas major lipids having phosphoserine head groups were found in M. smithii TPL. However, the divergent lipid compositions of other potent archaeosomes suggest that archaeal lipid structures in general can confer adjuvant activity. Interestingly, all three archaeosome preparations that induce the strongest responses had differentially localized (surface versus internalized) Ags (Table 1) . It is currently unknown whether the localization of the Ag on the archaeosome carrier is of significance to phagocytosis and presentation in vivo. However, the ability of archaeosomes with most of the Ag internalized to induce a strong primary immune response suggests vesicle degradation in vivo, leading to Ag release and presentation. This was particularly striking for T. acidophilum archaeosomes (with Ͼ80% internalized Ag), because these are composed primarily of caldarchaeol (tetraether) lipids known to form a monolayer arrangement by spanning the archaeosome membrane (5) and thus represent the most stable archaeosomes in vitro (35, 40) . However, conventional liposomes failed to induce strong antibody responses, even though Ͼ85% of the Ag was internalized within the vesicle, suggesting that immunomodulatory properties, along with in vivo stability and the ability to deliver Ag to Ag-presenting cells (APCs), are important for adjuvant activity.
Association of the Ag with the archaeosomes, as opposed to independent injections of the vesicle and Ag, yielded the strongest antibody response (Table 2 ). Liposomes are phagocytosed by APCs and have been used to deliver drugs and/or toxins to phagocytes (15, 44) . Thus, association of Ag with archaeosomal vesicles probably ensured direct delivery of the Ag to the APCs for effective processing and presentation. Indeed, we have noted that archaeosomes are phagocytosed to a greater extent than are conventional liposomes (43) . However, as some archaeosomes (M. espanolae and M. smithii) exhibited some adjuvant activity even when empty archaeosomes and Ag were injected separately, these appear to serve as both immunomodulators and Ag carriers.
As the genetic background of the host may differentially influence antigenic responses, the adjuvant activity of archaeosomes was assessed in different mouse strains. Three different mouse strains were chosen to reflect either a Th2-biased (BALB/c), a Th1-biased (C57BL/6), or an LPS-hyporesponsive (C3H/HeJ) host environment (6, 21, 33) . Although the overall magnitude of antibody response varied between the different mouse strains, archaeosomes generally induced humoral responses equalling or surpassing those of alum and FA in all strains (Fig. 1) .
Serum Ig isotype patterns of immunized mice revealed that both Ag-specific IgG1 and Ag-specific IgG2a antibodies were induced by the archaeosomes (Fig. 2) . As a strong humoral response and induction of IL-4 induce switching toward IgG1 and a cell-mediated response and induction of IFN-␥ induce switching to IgG2a (37), it appeared that both effector arms were influenced by archaeosomes. This was corroborated by the induction of Ag-specific proliferation (Fig. 5) , as well as the induction of cytokines IFN-␥ (Th1) and IL-4 (Th2) by spleen cells of archaeosome-immunized mice (Fig. 6) . In contrast, adjuvants such as alum (Fig. 6) (16) and CT (46) induce exclusively a Th2 response, while others such as immunostimulating complexes evoke primarily Th1 immunity (36) . Furthermore, the ability of archaeosomes to induce cell-mediated responses to various Ags (BSA, HEL, and OVA), as well as by different immunization routes, suggests a potential "universal" adjuvant function.
One of the important aspects of vaccine delivery is the ability to generate long-term memory. The failure of several initially protective vaccine formulations is due to the lack of this longterm effect. Although several archaeosomes induced a strong primary antibody response that was sustained for prolonged lengths of time (Ͼ100 days), this did not always correlate with a strong memory response. T. acidophilum archaeosomes induced the most dramatic memory response to antigenic challenge (Fig. 7) . The parallel induction of strong cell cycling in CD4 ϩ cells suggested efficient maintenance of T-cell memory as well (Fig. 8) . Memory T cells have been characterized as CD44
hi (11) . Interestingly, there was also a moderate increase (10 to 15%) in the expression of CD44 hi CD4 ϩ cells in the spleens of mice immunized with T. acidophilum archaeosomes (data not shown), reiterating the potent memory response. It has been suggested that Ag persistence may enhance the maintenance of long-term memory (4, 27) . The internalization of Ͼ80% of the Ag within T. acidophilum archaeosomes (Table 1), coupled with an anticipated in vivo stability of these unilayer caldarchaeol vesicles, may indeed have allowed maintenance of Ag for longer durations. Indeed, the less stable H. salinarum vesicles that had substantial amounts of the Ag localized on their surfaces (Ͻ60% internalized) induced a strong primary response but failed to induce a significant memory response. Overall, the availability of various archaeosome types that associate Ags differently may provide a convenient tool for modulation of primary and/or memory responses suited to a particular vaccine application.
Bacterial structures have provided a major source of immunoadjuvants. Peptidoglycans and the monophosphoryl lipid A or lipid A components of LPS are examples that can modulate the immune system without themselves being immunogenic (3) . Similarly, the advantage of archaeosomes appears to be in their ability to modulate both immune effector arms. Furthermore, we have not observed significant induction of antilipid antibodies after several repeated archaeosome immunizations (G. D. Sprott et al., unpublished observations). The exact mechanism(s) underlying the effectiveness of archaeosomes and other bacterial adjuvants remains unclear. Bacterial products may be immunomodulatory because they mimic the microbial structures that provide the danger signal of infection to the host (3). Moreover, the recognition of defined microbial components by phylogenetically ancient receptors present on APCs may result in immune activation. The presence of CD14, the LPS receptor on macrophages and neutrophils, is one such example (25) . Also, phosphatidylserine which is expressed on apoptotic cells and recognized by CD36 on macrophages (12) is found as archaetidylserine and caldarchaetidylserine analogs in the TPL of some archaeal strains, notably M. smithii (39) . Archaeosomes appear to be phagocytosed by APCs to a greater extent than conventional liposomes (43) . Whether this interaction is mediated by specific receptors and/or results in differential activation of the APCs, and thereby enhances Ag presentation, still needs to be determined.
In our earlier studies, we reported archaeosomes to be superior in inducing antibody responses to the entrapped Ag in comparison to several conventional liposome formulations (42) . In this study, we observed archaeosomes to be distinctly superior to conventional liposomes (DMPC-DMPG-CHOL) in their ability to induce cell-mediated immunity as well. Conventional liposomes have often been used to render protective protein and peptide Ags immunogenic, as well as to detoxify and/or deliver other potential adjuvants such as CT, lipid A, and cytokines (17, 23, 34) . Liposomes are versatile systems for effective delivery of Ags. However, the main impediments to the use of conventional liposomes as vaccine adjuvants have been the need to formulate complex mixtures with other immunoadjuvants, the consequent uncertainty of safety in humans, and the lack of cost-effectiveness in obtaining purified lipids. Archaeosomes may surpass such impediments, as they are independently effective and clearly superior to alum in their adjuvant action. Furthermore, M. smithii is a natural inhabitant of the human colon (28) , suggesting that lipids from such archaeobacteria may be most readily accepted for vaccine formulations. Our studies with mice so far have failed to indicate any archaeosome-related toxicity even in the long term. A lack of toxicity may stem from the eukaryote-like lipid structures, which bear phytanyl alkyl chains, as do fat-soluble vitamins. Indeed, a detailed study of mice with archaeosomes composed of the main polar lipid of T. acidophilum has indicated no toxicity (13) .
A number of immunoadjuvants including CT, lipid A, MF-59, and chitosan as well as particulate delivery systems such as ISCOMS, proteosomes, nonionic surfactant vesicles, and microspheres are being studied for their efficacy and potential use in humans (3, 24, 36) . The exponential rise in the number of adjuvants being tested in recent years emphasizes the critical need for novel universal immunostimulants for use with nextgeneration vaccines. The advantages of archaeosomes appear to be twofold: firstly in their ability to provide an antigenic depot like microspheres and conventional liposomes and secondly in their immunostimulation potential like that of CT, lipid A, and ISCOMS. As a carrier system, archaeosomes are highly stable (40) and capable of sustaining Ag for prolonged periods. As immunostimulants, archaeosomes induce both Th1 and Th2 responses. The efficacy of archaeosomes for protective immunization, their mechanism(s) of action, and safety require further study. Nevertheless, the available data indicate that archaeosomes may hold great promise as vaccine delivery vehicles.
